BioSpace News Archive

Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced successful results from an independent pre-clinical study validating the company’s Bio-RFID™ platform technology.

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that the Company will participate in upcoming investor and scientific conferences.

According to The Insight Partners market research study titled ‘Artificial Pancreas Device Systems Market to 2025 - Global Analysis and Forecasts by Type and Geography.

The market is estimated to grow with a CAGR of 3.8% from 2019-2027.

The report provides trends prevailing in the global radiofrequency ablation devices market and the factors driving market along with those that act as hindrances.

The U.S. Patent and Trademark Office has issued Concert Genetics patent US10,896,405B1 for innovative methods that enable real-time coverage determination and accurate reimbursement of genetic tests, the company announced today.

Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration approved expanded use of TRIKAFTA® to include children with cystic fibrosis ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or a mutation in the CFTR gene that is responsive to TRIKAFTA based on in vitro data.

A new claims analysis commissioned by GSK and conducted by Avalere Health, an Inovalon company, showed a sustained drop in immunization rates for recommended vaccines among teens and adults throughout the pandemic in 2020.

Enzo Biochem, Inc., a leading biosciences and diagnostics company, reported operating results for the third quarter ended April 30, 2021 and provided a business update on recent corporate and operational developments.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Sue-Jean Lin has been appointed to the Arcutis Board of Directors